Last edition
News about Global Pharma
Novartis AG Initiates Strategic Review of Novartis India Limited
While the strategic review progresses, it is essential to recognize that there is no guarantee of its completion within 2024.
Global Pharma | 19/02/2024 | By Manvi | 1309
PM Modi Lays Foundation Stone for AIIMS Rewari
Expressing his delight at the ceremony, PM Modi emphasized the rapid transformation of the healthcare sector in line with the aspirations of the people.
Global Pharma | 19/02/2024 | By Manvi | 675
CordenPharma and Pivot Energy Partners to Propel Renewable Energy Initiatives
Under the terms of the agreement, CordenPharma Colorado will tap into renewable energy generated by solar installations owned and operated by Pivot Energy.
Global Pharma | 16/02/2024 | By Manvi | 618
AMO Pharma's investigational oral glycogen synthase kinase 3 beta (GSK3β) inhibitor, in the treatment of genotype positive arrhythmogenic cardiomyopathy (ACM).
Global Pharma | 15/02/2024 | By Manvi | 807
Citius believes it has addressed enhanced product testing and additional manufacturing controls noted in the letter. There were no safety or efficacy issues cited and no additional trials required.
Global Pharma | 14/02/2024 | By Manvi | 699
Chanelle Pharma Acquired by Exponent, Marking a New Era
With over 730 employees across various locations, the company has established a strong foothold in Ireland, the UK, Europe, and Jordan.
Global Pharma | 14/02/2024 | By Manvi | 1265
Aurobindo Pharma Granted USFDA Approval for Deflazacort Tablets
The company plans to launch the product in February 2024.
Global Pharma | 14/02/2024 | By Manvi | 838
Born from the amalgamation of six asset-centric Medicxi companies, Alys aims to revolutionize dermatological treatments with its innovative programs and platforms targeting various dermatological indications.
Global Pharma | 13/02/2024 | By Manvi | 1222
Aparna Organics Receives USFDA VAI Classification for Manufacturing Facility
Its manufacturing facility, Aparna Organics, located in Pydibhimavaram, Srikakulam, Andhra Pradesh, has been awarded the VAI classification by the USFDA.
Global Pharma | 13/02/2024 | By Manvi | 1283
Lykos Therapeutics Announces FDA Acceptance
The FDA has granted the application priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 11, 2024.
Global Pharma | 10/02/2024 | By Manvi | 746
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy